

NEUROLOGIX INC/DE  
Form 8-K  
May 26, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 26, 2011

---

Neurologix, Inc.  
(Exact Name of Registrant as Specified in its Charter)

---

Delaware (State or other jurisdiction of incorporation)	000-13347 (Commission File Number)	06-1582875 (IRS Employer Identification Number)
One Bridge Plaza, Fort Lee, New Jersey 07024 (Address of principal executive offices)		
(201) 592-6451 (Registrant's telephone number, including area code)		

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

(17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  
(17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On May 26, 2011, Michael G. Kaplitt, M.D., Ph.D., one of the scientific co-founders of Neurologix, Inc., is making a presentation at the International Neuromodulation Society 10th World Congress in London, England. Such presentation will include a discussion and slide show presentation of previously unreported one-year efficacy results of Neurologix, Inc.'s Phase 2 trial for Parkinson's disease. A copy of the slides related to such results, substantially in the form to be used by Dr. Kaplitt, is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On May 26, 2011, Neurologix, Inc. issued a press release regarding Dr. Kaplitt's presentation at the International Neuromodulation Society 10th World Congress in London, England, as described above. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit

Number	Description
99.1	Slides related to one-year efficacy results of Neurologix, Inc's Phase 2 trial for Parkinson's disease (furnished pursuant to Item 7.01 of Form 8-K).
99.2	Press Release of Neurologix, Inc., dated May 26, 2011 (furnished pursuant to Item 7.01 of Form 8-K).

---

Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROLOGIX, INC.

Date: May 26, 2011

By: /s/ Marc L. Panoff  
Name: Marc L. Panoff  
Title: Chief Financial Officer, Secretary and Treasurer

---

EXHIBIT INDEX

Exhibit	Description
99.1	Slides related to one-year efficacy results of Neurologix, Inc's Phase 2 trial for Parkinson's disease (furnished pursuant to Item 7.01 of Form 8-K).
99.2	Press Release of Neurologix, Inc., dated May 26, 2011 (furnished pursuant to Item 7.01 of Form 8-K).

---